Fort Washington Investment Advisors 13F: Adds $53M to SYK Stake

Fort Washington Investment Advisors has increased its stake in Stryker Corporation (NYSE: SYK) by 193,420 shares. This brings its total holdings to 367,335 shares, valued at approximately $101.2 million. The filing was made on October 15, 2026, and reflects the fund's increasing confidence in the medical technology company.

What Changed in Fort Washington's Stryker Position

The boost in position represents an impressive 111.2% increase for Fort Washington. Prior to this change, the fund held 173,915 shares. The increase shows a clear commitment to Stryker, suggesting that Fort Washington sees value in the company’s growth potential despite recent market fluctuations.

Other Institutional Activity in Stryker

In the latest filings, several notable institutional investors have also adjusted their positions in Stryker. JPMorgan Chase & Co. added 1,664,175 shares, raising their total to 17,260,943 shares worth about $5.1 billion. Vanguard Capital Management LLC increased its holdings by 154,439 shares to a total of 22,536,843 shares valued at approximately $6.6 billion. State Street Corporation added 182,664 shares, bringing its total to 15,532,565 shares worth about $4.6 billion. These movements indicate a mix of confidence and caution among major investors in Stryker.

Stryker Corporation Stock Up 4.4%

As of October 16, 2026, Stryker shares were trading recently around $294.09, which is about 2.2% below the 50-day moving average of $300.80 and 10% below the 200-day moving average of $326.94. The stock is currently trading 25.1% below its 52-week high of $392.55 but 10.1% above its 52-week low of $267.00. This positioning could reflect investor sentiment as they adjust to broader market conditions.

Recent Earnings

Stryker reported trailing twelve-month revenue of approximately $25.8 billion and an earnings per share (EPS) of $9.65, indicating solid financial performance. The company has a net margin of 14.4% and a return on equity of 16.5%. The next earnings report is expected on October 29, 2026, providing further insights into its financial health.

Insider Buying and Selling at Stryker Corporation

In recent insider transactions, several officers sold shares earlier this year. Robert S. Fletcher, an officer, sold 4,544 shares on May 28, 2026, valued at about $1.4 million. Debra King and Ronda E. Stryker also sold shares on August 18 and August 19, respectively. These trades indicate some movement among insiders, though it does not necessarily reflect a bearish outlook.

Analysts Set New Price Targets

Before October 15, several analysts maintained their positions on Stryker. On September 22, 2026, TD Cowen maintained a "Hold" rating with a target price of $298, while Stifel maintained a "Buy" rating with a target of $330 on September 30. Barclays initiated an "Overweight" rating with a target of $375 on October 7. The consensus among analysts is positive, with a mean price target of $362.62 and a recommendation of "buy."

About Stryker Corporation

Stryker Corporation operates as a major player in the medical technology sector, focusing on developing medical devices and equipment. The company works through segments like MedSurg and Neurotechnology, as well as Orthopaedics. This recent position boost by Fort Washington shows growing confidence in Stryker's potential within the healthcare industry.

Bottom Line

Investors will be watching Stryker closely as it approaches its next earnings date on October 29, 2026. Fort Washington's recent filing reflects its holdings as of the reporting period and may not represent the current position. As always, it's important to consider that institutional positions can change rapidly based on market conditions.